Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Sensyne Health | Healthcare

MagnifEye allows standardisation of test reporting, thereby increasing confidence in LFD testing, reducing user error and increasing overall accuracy of an AI LFD programme.1

AI-powered reading and analysis of diagnostic tests

The COVID-19 pandemic has increased the need for accurate reading of point-of-care diagnostic tests for clinical decision support and disease surveillance across large populations.

MagnifyEye utilises Sensyne’s expertise in developing novel deep learning approaches and AI algorithms to automate and improve the accuracy of reading diagnostic tests across a wide range of indications including COVID-19.

Potential benefits

Improves reading accuracy and consistency

Reduces the variability, subjectivity and possible error associated with manual, unassisted image reading.

Epidemiological insight

Analysis of large image datasets may help inform disease and public health management.

Speed and flexibility

Results are returned in under 2 seconds, and available for analysis immediately, improving user adoption and supporting decision making.


Data is encrypted and securely held in the cloud with robust cyber security.

A proven tested technology

NHS Digital conducted a pilot study in April 2021 that tested MagnifEye on over 100,000 real world cases.  The results of the pilot study1 show:

MagnifEye increased sensitivity (the ability to identify positive tests correctly) to 97.6% and specificity (the ability to identify negative tests correctly) to 99.99% in reading lateral flow tests, as compared to a human reader.

Overall accuracy

A significant proportion of positive cases that were previously missed by users or trained lateral flow test readers were detected by MagnifEye. At Assisted Testing Sites (ATSs) the algorithm identified 24.4% of true positive tests that were missed by trained operators.

Ongoing use of this algorithm is anticipated to support the Government in identifying positive cases with low viral loads which might otherwise be missed via human read and improve objective reading of tests by supporting the visually impaired or anxious in interpretation of their COVID lateral flow results.

MagnifEye is aimed at

Diagnostic test providers and manufacturers requiring faster, more accurate reporting of test results.
Public health agencies requiring rapid, accurate test reporting and analysis for epidemiological insights.


What is MagnifEye?
What format is it available in?
What problem does it help solve?
Who is it aimed at?
How does it benefit patients and clinicians?
What types of test can be read using MagnifEye?
How is MagnifEye different to other lateral flow test readers?
How could this technology help individuals during the current pandemic?
How widespread are COVID-19 lateral flow tests right now in the UK and elsewhere, and how do you see their use evolving in the coming months?
Can MagnifEye help improve the accuracy of lateral flow tests?
Do all lateral flow tests need dedicated readers to interpret the results accurately?  
Why has Sensyne developed this product?
How is the image data stored?
How will data be used?
How do you protect personal and healthcare data?